125
Participants
Start Date
August 9, 2022
Primary Completion Date
March 24, 2025
Study Completion Date
March 24, 2025
Tezepelumab
Tezepelumab subcutaneous injection
Placebo
Placebo subcutaneous injection
Research Site, Bangkok
Research Site, The Bronx
Research Site, Bang Kra So
Research Site, Lima
Research Site, Bursa
Research Site, Suwon
Research Site, Newark
Research Site, Bychawa
Research Site, Miami Lakes
Research Site, Hialeah
Research Site, Istanbul
Research Site, Izmir
Research Site, Guadalajara
Research Site, Guadalajara
Research Site, Guadalajara
Research Site, Monterrey
Research Site, Moravský Krumlov
Research Site, Lincoln
Research Site, Kingwood
Research Site, San Luis Potosí City
Research Site, El Paso
Research Site, Denver
Research Site, Hat Yai
Research Site, Veracruz
Research Site, Newport Beach
Research Site, Kanpur
Research Site, Ajmer
Research Site, Vadodara
Research Site, Curicó
Research Site, Santiago
Research Site, Santiago
Research Site, Santiago
Research Site, Santiago
Research Site, Santiago
Research Site, Santiago
Research Site, Santiago
Research Site, Porto Alegre
Research Site, Botucatu
Research Site, Curitiba
Research Site, Porto Alegre
Research Site, Salvador
Research Site, São Bernardo do Campo
Research Site, São Paulo
Research Site, Sorocaba
Research Site, Ajax
Research Site, Québec
Research Site, Brno
Research Site, Hradec Králové
Research Site, Jindřichův Hradec
Research Site, Olomouc
Research Site, Ostrava
Research Site, Mexico City
Research Site, Bialystok
Research Site, Bydgoszcz
Research Site, Chęciny
Research Site, Grudziądz
Research Site, Ostrowiec Świętokrzyski
Research Site, Poznan
Research Site, Rzeszów
Research Site, Sosnowiec
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Ankara
Lead Sponsor
Collaborators (1)
Amgen
INDUSTRY
AstraZeneca
INDUSTRY